Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Bimatoprost
102
CHF
CHF 102.00
In stock
CDX-P0325-M0011 mgCHF 102.00
CDX-P0325-M0055 mgCHF 401.00
| Product Details | |
|---|---|
| Synonyms | 17-Phenyl-tri-norprostaglandin F2α-ethyl amide; cGMP Bimatoprost; AGN-192024; Lumigan; Prostamide |
| Product Type | Chemical |
| Properties | |
| Formula |
C25H37NO4 |
| MW | 415.57 |
| CAS | 155206-00-1 |
| Purity Chemicals | ≥95% (HPLC) |
| Appearance | White powder. |
| Solubility | Soluble in DMSO. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | AQOKCDNYWBIDND-FTOWTWDKSA-N |
| Smiles | O[C@H]1C[C@@H](O)[C@H](/C=C/[C@@H](O)CCC2=CC=CC=C2)[C@H]1C/C=C\CCCC(NCC)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Bimatoprost is a synthetic prostamide FP receptor agonist, structurally related to prostaglandin F2α that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. Bimatoprost is therefore an antiglaucoma agent. Bimatoprost is converted by an amidase enzymatic activity to yield the corresponding free acid, 17-phenyl trinor PGF2α, a potent PGF2αR agonist. In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity.
Product References
(1) L.B. Cantor, et al.; Expert Opin. Investig. Drugs 10, 721 (2001) (Review) | (2) R.F. Brubaker; Surv. Ophthalmol. 45, S347 (2001) (Review) | (3) A.H. Krauss & D.F. Woodward; Surv. Ophthalmol. 49, S5 (2004) (Review) | (4) D.F. Woodward, et al.; Cardiovasc. Drug Rev. 22, 103 (2004) (Review)